Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Perspective Therapeutics (NASDAQ:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference